Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains killed virus particles that present hemagglutinin and neuraminidase antigens to the immune system. After injection, antigen‑presenting cells process these proteins, activating T‑cells and prompting B‑cells to produce strain‑specific antibodies. These antibodies can neutralize the corresponding live viruses if the person is later exposed.

The dose of Influvac is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunization guidelines. The vaccine is typically given as a single intramuscular or subcutaneous injection per season, but the exact volume and schedule are set by the prescriber.

Data on the use of inactivated influenza vaccines like Influvac during pregnancy are limited, but such vaccines are generally considered safe when the potential benefits outweigh any theoretical risks. Breastfeeding mothers should consult their healthcare provider to decide whether vaccination is appropriate for them and their infant.

To order Influvac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics—and any necessary import documentation.

Influvac is an inactivated, trivalent formulation targeting the B/Austria/1359417/2021-like and A/Vic strains, whereas many modern vaccines are quadrivalent and include additional A/H3N2 or B/Victoria lineages. Inactivated vaccines are suitable for immunocompromised patients and do not carry a risk of live virus replication, but the breadth of protection may differ from broader‑spectrum quadrivalent options.

Influvac must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Influvac is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. The injection site should be cleaned with an appropriate antiseptic, and the dose is given as a single shot per vaccination season unless otherwise directed by a clinician.

The most serious adverse events reported with influenza vaccines include severe allergic reactions (anaphylaxis) and, rarely, neurological conditions such as Guillain‑Barré syndrome. These events are uncommon, but patients should be observed for a short period after vaccination and seek immediate medical care if symptoms of a severe reaction develop.

Influvac should not be given to individuals with a known severe allergy to any component of the vaccine or to those who have experienced a serious reaction to a previous dose of the same vaccine. Persons with acute moderate or severe illness should defer vaccination until recovery. Consultation with a healthcare provider is essential for anyone with underlying health concerns.